Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial Swords, R. T., Savona, M. R., Maris, M. B., Erba, H. P., Berdeja, J. G., Foran, J. M., Hua, Z., Faessel, H. M., Dash, A. B., Sedarati, F., Dezube, B. J., Medeiros, B. C. AMER SOC HEMATOLOGY. 2014
View details for Web of Science ID 000349243505126